This document is an excerpt from the EUR-Lex website
Document 62021TN0346
Case T-346/21: Action brought on 23 June 2021 — Hecht Pharma v EUIPO — Gufic Biosciences (Gufic)
Case T-346/21: Action brought on 23 June 2021 — Hecht Pharma v EUIPO — Gufic Biosciences (Gufic)
Case T-346/21: Action brought on 23 June 2021 — Hecht Pharma v EUIPO — Gufic Biosciences (Gufic)
OJ C 329, 16.8.2021, p. 36–36
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
16.8.2021 |
EN |
Official Journal of the European Union |
C 329/36 |
Action brought on 23 June 2021 — Hecht Pharma v EUIPO — Gufic Biosciences (Gufic)
(Case T-346/21)
(2021/C 329/47)
Language in which the application was lodged: German
Parties
Applicant: Hecht Pharma GmbH (Bremervörde, Germany) (represented by: C. Sachs and J. Sachs, lawyers)
Defendant: European Union Intellectual Property Office (EUIPO)
Other party to the proceedings before the Board of Appeal: Gufic Biosciences Ltd. (Mumbai, India)
Details of the proceedings before EUIPO
Proprietor of the trade mark at issue: Other party to the proceedings before the Board of Appeal
Trade mark at issue: EU word mark Gufic — EU trade mark No 8 613 044
Procedure before EUIPO: Cancellation proceedings
Contested decision: Decision of the Second Board of Appeal of EUIPO of 3 June 2021 in Case R 2738/2019-2
Form of order sought
The applicant claims that the Court should:
|
— |
annul the contested decision and also declare EU trade mark No 8 613 044 ‘Gufic’ revoked in respect of Class 5 ‘Medicines’; |
|
— |
order Gufic Biosciences Ltd. to pay the costs of the appeal proceedings and of the pre-litigation procedure. |
Plea in law
|
— |
Infringement of Article 58(1) of Regulation (EU) 2017/1001 of the European Parliament and of the Council. |